A Prospective, Single-Arm, Open-label Study to Investigate the Efficacy and Safety of Intravesical Injection of Botulinum Toxin Type-A (750 Units Dysport) for the Management of Neurogenic Detrusor Overactivity.
Phase of Trial: Phase II
Latest Information Update: 25 May 2011
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 25 May 2011 New trial record